All In Biotech

Drug Trial Radar · NCT00999609

Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis

A Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis (LCA) Using Adeno-Associated Viral Vector to Deliver the Gene for Human RPE65 to the Retinal Pigment Epithelium (RPE) [AAV2-hRPE65v2-301]

Last checked: Nov 20, 2026Latest source record: Apr 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

31

Actual

Start

Oct 2012

Primary completion

Jul 2015

Study completion Jan 2030

Sponsor

Lead sponsor
Spark Therapeutics, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
Children's Hospital of Philadelphia; University of Iowa
First posted
Oct 22, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 3 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a Phase 3, open-label, randomized controlled trial of gene therapy intervention by subretinal administration of AAV2-hRPE65v2 (voretigene neparvovec-rzyl). At least twenty-four subjects, three years of age or older, will be recruited. The intervention group will receive AAV2-hRPE65v2 at either The Children's Hospital of Philadelphia or University of Iowa to determine if it improves visual and retinal function in individuals with RPE65 gene mutations.

Conditions

  • Inherited Retinal Dystrophy Due to RPE65 Mutations
  • Leber Congenital Amaurosis

Interventions

  • AAV2-hRPE65v2,voretigene neparvovec-rzylBiological

    Subretinal administration of gene therapy vector AAV2-hRPE65v2 (1.5E11 vector genomes per eye) to both eyes via surgical procedures on separate days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Multi-luminance Mobility Testing (MLMT), BilateralTime frame: One year (change from baseline)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • University of Iowa

    Iowa City, Iowa

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.